Like

Scottish biotech TC BioPharm lowers deal size by 40%, adds warrants ahead of $30 million US IPO

TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies,
Scottish biotech TC BioPharm lowers deal size by 40%, adds warrants ahead of $30 million US IPO

免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。

举报

评论1

  • 推荐
  • 最新
empty
暂无评论